The downregulation of the FOS gene has been identified in aggressive breast cancer subtypes, including basal, HER2-positive, and luminal B cases, with decreased expression levels correlating with advanced cancer stages [50]. This evidence concerns the gene ERBB2 and breast carcinoma.